瑞舒伐他汀与阿托伐他汀治疗冠心病的临床应用效果比较

摘要
图/表
参考文献(15)
相关文章 (15)

全文: PDF (0 KB) HTML (32 KB)
输出: BibTeX | EndNote (RIS)

摘要目的比较瑞舒伐他汀与阿托伐他汀治疗冠心病的临床应用效果。方法选取2018年4月～2019年4月沈阳医学院附属第二医院收治的500例冠心病患者作为研究对象，通过动态化随机分为试验组与对照组，每组各250例。试验组患者采取瑞舒伐他汀治疗，对照组患者采取阿托伐他汀治疗。比较两组患者的临床疗效、心功能指标、血脂水平以及不良反应发生情况。结果试验组患者的治疗总有效率（96.00%）高于对照组（70.00%），差异有统计学意义（P＜0.05）。治疗后，两组患者的左室射血分数（LVEF）均高于治疗前，左室舒张末期内径（LVEDD）均低于治疗前，差异有统计学意义（P＜0.05）；治疗后，试验组患者的LVEF 高于对照组，LVEDD 低于对照组，差异有统计学意义（P＜0.05）。治疗后，两组患者的三酰甘油、总胆固醇、低密度脂蛋白含量均低于治疗前，高密度脂蛋白高于治疗前，差异有统计学意义（P＜0.05）；治疗后，试验组患者的三酰甘油、总胆固醇、低密度脂蛋白含量低于对照组，高密度脂蛋白含量高于对照组，差异有统计学意义（P＜0.05）。试验组患者的不良反应总发生率（4.80%）低于对照组（12.80%），差异有统计学意义（P＜0.05）。结论瑞舒伐他汀治疗冠心病患者可提高临床效果，有效改善心功能指标和血脂指标，用药安全性较高，值得临床推广应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘佳妮

关键词 ：瑞舒伐他汀, 阿托伐他汀, 冠心病, 应用效果

Abstract：Objective To compare the clinical effect of Rosuvastatin and Atorvastatin in the treatment of coronary heart disease.Methods A total of 500 patients with coronary heart disease who admitted to the Second Affiliated Hospital of Shenyang Medical College from April 2018 to April 2019 were selected as the research objects and randomly divided into the experimental group and the control group by dynamics，with 250 cases in each group.The experimental group was treated with Rosuvastatin and the control group was treated with Atorvastatin.The clinical efficacy，cardiac function indexes，blood lipid levels and adverse reactions were compared between the two groups of patients.Results The total effective rate of the experimental group (96.00%) was higher than that of the control group (70.00%)，and the difference was statistically significant (P＜0.05).After treatment，the left ventricular ejection fraction (LVEF) of the two groups was higher than that before treatment，the left ventricular end diastolic diameter (LVEDD) of the two groups was lower than that before treatment，and the differences were statistically significant (P＜0.05).After treatment，the LVEF of the experimental group was higher than that of the control group，the LVEDD of the experimental group was lower than that of the control group，and the differences were statistically significant (P＜0.05).After treatment，the triglyceride，total cholesterol，and low-density lipoprotein of the two groups were lower than those before treatment，high-density lipoprotein contents of the two groups were higher than those before treatment，and the differences were statistically significant (P＜0.05).After treatment，triglyceride，total cholesterol，low-density lipoprotein of the experimental group were lower than those of the control group，high-density lipoprotein of the experimental group was higher than that of the control group，and the differences were statistically significant (P＜0.05).The total incidence of adverse reactions in experimental group (4.80%) was lower than that in the control group (12.80%)，and the difference was statistically significant (P＜0.05).Conclusion Rosuvastatin in the treatment of patients with coronary heart disease can improve the clinical efficacy，effectively improve blood lipid indexes and cardiac function indexes，and the drug is safer，so it is worthy of clinical promotion and application.

Key words： Rosuvastatin Atorvastatin Coronary heart disease Application effect

引用本文:

刘佳妮. 瑞舒伐他汀与阿托伐他汀治疗冠心病的临床应用效果比较[J]. 中国当代医药, 2020, 27(33): 70-72.
LIU Jia-ni. Clinical application effect comparison of Rosuvastatin and Atorvastatin in the treatment of coronary heart disease. 中国当代医药, 2020, 27(33): 70-72.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2020/V27/I33/70

[1]	马睿.国产瑞舒伐他汀与阿托伐他汀对老年冠心病患者血脂及炎症因子的影响评价[J].中西医结合心血管病电子杂志，2018，6（19）：195-196.
[2]	张艳辉，邢佳侬，戚秀娟，等.瑞舒伐他汀与阿托伐他汀对冠心病心绞痛患者的疗效及血脂的影响[J].心血管康复医学杂志，2018，27（2）：154-157.
[3]	张菲菲.冠心病慢性心力衰竭患者应用不同剂量阿托伐他汀与瑞舒伐他汀的临床疗效对比及其安全性分析[J].药物生物技术，2018，25（2）：153-156.
[4]	林常.瑞舒伐他汀与阿托伐他汀对冠心病急性心肌梗死患者介入治疗后血脂水平、血液流变学水平及内皮功能的影响[J].中国现代药物应用，2018，12（7）：108-109.
[5]	许建宗，薛静.冠心病分别采用瑞舒伐他汀以及阿托伐他汀治疗的临床效果及其安全性[J].临床医药文献电子杂志，2019，6（81）：168-169.
[6]	额尔敦巨日河.瑞舒伐他汀与阿托伐他汀对冠心病伴高脂血症患者的临床疗效和安全[J].世界最新医学信息文摘，2019，19（47）：350-351.
[7]	朱婧懿，唐进松，宋彦丽，等.瑞舒伐他汀与阿托伐他汀治疗冠心病患者高血脂的疗效观察[J].解放军药学学报，2018，34（1）：92-94.
[8]	吴丽丽，吴梅梅.瑞舒伐他汀与阿托伐他汀在治疗冠心病患者中的疗效与安全性分析[J].贵州医药，2019，43（9）：1400-1401.
[9]	刘国欢，蒋爱忠，杨爽.瑞舒伐他汀与阿托伐他汀治疗冠心病的临床效果探讨[J].中国实用医药，2019，14（26）：56-57.
[10]	封和.瑞舒伐他汀与阿托伐他汀治疗冠心病的对比及对TNF-α、IL-6、CRP 的影响[J].现代医学与健康研究电子杂志，2019，3（17）：57-59.
[11]	李波涛.对比分析瑞舒伐他汀和阿托伐他汀对冠心病患者的调脂、非调脂作用及对动脉粥样硬化的逆转作用和安全性[J].医学食疗与健康，2019（13）：35-36.
[12]	黄灿.瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效及安全性比较[J].中西医结合心血管病电子杂志，2019，7（17）：33-34.
[13]	王兴华，付文亭.瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效分析[J].世界复合医学，2019，5（7）：153-155.
[14]	杨晓榆.瑞舒伐他汀与阿托伐他汀对冠心病患者血清脂肪因子Vaspin 的影响[J].临床医药文献电子杂志，2019，6（36）：43-44.
[15]	何崇.阿托伐他汀与瑞舒伐他汀治疗冠心病患者的疗效比较[J].临床合理用药杂志，2019，12（32）：5-6.